28.26
+0.42(+1.51%)
Currency In USD
| Previous Close | 27.84 |
| Open | 27.89 |
| Day High | 29.33 |
| Day Low | 27.13 |
| 52-Week High | 92 |
| 52-Week Low | 10.06 |
| Volume | 60,893 |
| Average Volume | 326,011 |
| Market Cap | 190.77M |
| PE | -2.19 |
| EPS | -12.91 |
| Moving Average 50 Days | 27.77 |
| Moving Average 200 Days | 22.95 |
| Change | 0.42 |
If you invested $1000 in Instil Bio, Inc. (TIL) since IPO date, it would be worth $53.44 as of August 18, 2025 at a share price of $28.26. Whereas If you bought $1000 worth of Instil Bio, Inc. (TIL) shares 3 years ago, it would be worth $222.17 as of August 18, 2025 at a share price of $28.26.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
GlobeNewswire Inc.
Jul 31, 2025 10:00 AM GMT
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line N
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
GlobeNewswire Inc.
Jul 02, 2025 10:00 AM GMT
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE N
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
GlobeNewswire Inc.
Jun 11, 2025 11:00 AM GMT
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Boar